The hallmarks of Parkinson's disease

FEBS Journal

Volumn 280, Issue 23, 2013, Pages 5981-5993

  Antony, Paul M A ^a   Diederich, Nico J ^a,b   Krüger, Rejko ^c,d   Balling, Rudi ^a  

^a UNIVERSITY OF LUXEMBOURG   (Luxembourg)

^b CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

cellular hallmarks; environmental factors; genetic factors; Parkinson's disease; systems biology; translational research

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AGRICULTURAL CHEMICAL; ALPHA SYNUCLEIN; CALCIUM ION; COPPER; DJ 1 PROTEIN; INSECTICIDE; IRON; PARKIN; REACTIVE OXYGEN METABOLITE; ZINC;

AGE; ALPHA SYNUCLEIN GENE; AUTOPHAGY; DOPAMINERGIC NERVE CELL; ENVIRONMENTAL EXPOSURE; GENE MUTATION; GENETIC RISK; HUMAN; IRON STORAGE; LEWY BODY; LYSOSOME; MICROGLIA; MITOCHONDRION; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; REVIEW; SUBSTANTIA NIGRA; SYNAPSE; TRANSLATIONAL RESEARCH;

CELLULAR HALLMARKS; ENVIRONMENTAL FACTORS; GENETIC FACTORS; PARKINSON'S DISEASE; SYSTEMS BIOLOGY; TRANSLATIONAL RESEARCH;

DISEASE PROGRESSION; HUMANS; PARKINSON DISEASE; PHENOTYPE; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY;

EID: 84888287211     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12335     Document Type: Review

References (120)

1. Ling H, Massey L, Lees AJ, Brown P, &, Day BL, (2012) Hypokinesia without decrement distinguishes progressive supranuclear palsy from Parkinson's disease. Brain 135, 1141-1153.
2. Gallagher D, Lees AJ, &, Schrag A, (2010) What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them? Mov Disord 25, 2493-2500.
3. Park A, &, Stacy M, (2009) Non-motor symptoms in Parkinson's disease. J Neurol 256 (Suppl), 293-298.
4. Simuni T, &, Sethi K, (2008) Nonmotor manifestations of Parkinson's disease. Ann Neurol 64 (Suppl 2), S65-S80.
5. Postuma RB, Aarsland D, Barone P, Burn DJ, Hawkes CH, Oertel W, &, Ziemssen T, (2012) Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. Mov Disord 27, 617-626.
6. Hanahan D, &, Weinberg RA, (2000) The hallmarks of cancer. Cell 100, 57-70.
7. Hanahan D, &, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144, 646-674.
8. De Lau LML, &, Breteler MMB, (2006) Epidemiology of Parkinson's disease. Lancet Neurol 5, 525-535.
9. Nussbaum RL, &, Ellis CE, (2003) Alzheimer's disease and Parkinson's disease. N Engl J Med 348, 1356-1364.
10. Crosiers D, Theuns J, Cras P, &, Van Broeckhoven C, (2011) Parkinson disease: insights in clinical, genetic and pathological features of monogenic disease subtypes. J Chem Neuroanat 42, 131-141.
11. Hindle JV, (2010) Ageing, neurodegeneration and Parkinson's disease. Age Ageing 39, 156-161.
12. Klein C, &, Westenberger A, (2012) Genetics of Parkinson's disease. Cold Spring Harb Perspect Med 2, 1-15.
13. Singleton AB, Farrer MJ, &, Bonifati V, (2013) The genetics of Parkinson's disease: progress and therapeutic implications. Mov Disord 28, 14-23.
14. Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E, Deligtisch A, Tagliati M, Hunt AL, Klein C, Henick B, Hailpern SM, et al,. (2006) LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 354, 424-425.
15. Goldwurm S, Zini M, Mariani L, Tesei S, Miceli R, Sironi F, Clementi M, Bonifati V, &, Pezzoli G, (2007) Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in Parkinson disease. Neurology 68, 1141-1143.
16. Ramirez A, Heimbach A, Gründemann J, Stiller B, Hampshire D, Cid LP, Goebel I, Mubaidin AF, Wriekat A-L, Roeper J, et al,. (2006) Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 38, 1184-1191.
17. Langston JW, &, Ballard PA, (1983) Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N Engl J Med 309, 310.
18. Mizuno Y, Suzuki K, Sone N, &, Saitoh T, (1988) Inhibition of mitochondrial respiration by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse brain in vivo. Neurosci Lett 91, 349-353.
19. Thiruchelvam M, Richfield EK, Baggs RB, Tank AW, &, Cory-Slechta DA, (2000) The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. J Neurosci 20, 9207-9214.
20. Priyadarshi A, Khuder S, Schaub E, &, Priyadarshi SS, (2001) Environmental risk factors and Parkinson's disease: a metaanalysis. Environ Res 86, 122-127.
21. Uversky VN, (2004) Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res 318, 225-241.
22. Kieburtz K, &, Wunderle KB, (2013) Parkinson's disease: evidence for environmental risk factors. Mov Disord 28, 8-13.
23. Gash DM, Rutland K, Hudson NL, Sullivan PG, Bing G, Cass WA, Pandya JD, Liu M, Choi D-Y, Hunter RL, et al,. (2008) Trichloroethylene: parkinsonism and complex 1 mitochondrial neurotoxicity. Ann Neurol 63, 184-192.
24. Goldman SM, Quinlan PJ, Ross GW, Marras C, Meng C, Bhudhikanok GS, Comyns K, Korell M, Chade AR, Kasten M, et al,. (2012) Solvent exposures and Parkinson disease risk in twins. Ann Neurol 71, 776-784.
25. Wirdefeldt K, Adami H-O, Cole P, Trichopoulos D, &, Mandel J, (2011) Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol 26 (Suppl 1), S1-S58.
26. Simõn-Sánchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-Ruiz C, Lichtner P, Scholz SW, Hernandez DG, et al,. (2009) Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 41, 1308-1312.
27. Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, Kawaguchi T, Tsunoda T, Watanabe M, Takeda A, et al,. (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 41, 1303-1307.
28. Sheng Z-H, &, Cai Q, (2012) Mitochondrial transport in neurons: impact on synaptic homeostasis and neurodegeneration. Nat Rev Neurosci 13, 77-93.
29. Mazzulli JR, Xu Y-H, Sun Y, Knight AL, McLean PJ, Caldwell G, Sidransky E, Grabowski G, &, Krainc D, (2011) Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146, 37-52.
30. Braak H, Del Tredici K, Rüb U, De Vos RAI, Jansen Steur ENH, &, Braak E, (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24, 197-211.
31. Hawkes CH, Del Tredici K, &, Braak H, (2009) Parkinson's disease: the dual hit theory revisited. Ann N Y Acad Sci 1170, 615-622.
32. Olanow CW, &, Prusiner SB, (2009) Is Parkinson's disease a prion disorder? Proc Natl Acad Sci USA 106, 12571-12572.
33. Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, &, Lee VM-Y, (2012) Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949-953.
34. Desplats P, Lee H-J, Bae E, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, &, Lee S-J, (2009) Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci USA 106, 13010-13015.
35. Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A, Meaney DF, Trojanowski JQ, &, Lee VM-Y, (2011) Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72, 57-71.
36. Kordower JH, Chu Y, Hauser RA, Freeman TB, &, Olanow CW, (2008) Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 14, 504-506.
37. Li J-Y, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehncrona S, Björklund A, et al,. (2008) Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 14, 501-503.
38. Pan-Montojo F, Schwarz M, Winkler C, Arnhold M, O'Sullivan G, Pal A, Said J, Marsico G, Verbavatz J-M, Rodrigo-Angulo M, et al,. (2012) Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. Sci Rep 2, 1-12.
39. Pan-Montojo F, Anichtchik O, Dening Y, Knels L, Pursche S, Jung R, Jackson S, Gille G, Spillantini MG, Reichmann H, et al,. (2010) Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS ONE 5, 1-10.
40. Korolchuk VI, Menzies FM, &, Rubinsztein DC, (2010) Mechanisms of cross-talk between the ubiquitin-proteasome and autophagy-lysosome systems. FEBS Lett 584, 1393-1398.
41. Chu Y, Dodiya H, Aebischer P, Olanow CW, &, Kordower JH, (2009) Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol Dis 35, 385-398.
42. Lee J, Giordano S, &, Zhang J, (2012) Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling. Biochem J 441, 523-540.
43. Shiba-Fukushima K, Imai Y, Yoshida S, Ishihama Y, Kanao T, Sato S, &, Hattori N, (2012) PINK1-mediated phosphorylation of the Parkin ubiquitin-like domain primes mitochondrial translocation of Parkin and regulates mitophagy. Sci Rep 2, 1002.
44. Martinez-Vicente M, Talloczy Z, Kaushik S, Massey AC, Mazzulli JR, Mosharov EV, Hodara R, Fredenburg R, Wu D-C, Follenzi A, et al,. (2008) Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest 118, 777-788.
45. Dehay B, Martinez-Vicente M, Ramirez A, Perier C, Klein C, Vila M, &, Bezard E, (2012) Lysosomal dysfunction in Parkinson disease: ATP13A2 gets into the groove. Autophagy 8, 1389-1391.
46. Clark IE, Dodson MW, Jiang C, Cao JH, Huh JR, Seol JH, Yoo SJ, Hay BA, &, Guo M, (2006) Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 441, 1162-1166.
47. Exner N, Treske B, Paquet D, Holmström K, Schiesling C, Gispert S, Carballo-Carbajal I, Berg D, Hoepken H-H, Gasser T, et al,. (2007) Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J Neurosci 27, 12413-12418.
48. Gegg ME, Cooper JM, Schapira AHV, &, Taanman J-W, (2009) Silencing of PINK1 expression affects mitochondrial DNA and oxidative phosphorylation in dopaminergic cells. PLoS ONE 4, 1-10.
49. Geisler S, Holmström KM, Skujat D, Fiesel FC, Rothfuss OC, Kahle PJ, &, Springer W, (2010) PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat Cell Biol 12, 119-131.
50. Abramov AY, Gegg M, Grunewald A, Wood NW, Klein C, &, Schapira AHV, (2011) Bioenergetic consequences of PINK1 mutations in Parkinson disease. PLoS ONE 6, 1-9.
51. Lev N, Ickowicz D, Melamed E, &, Offen D, (2008) Oxidative insults induce DJ-1 upregulation and redistribution: implications for neuroprotection. Neurotoxicology 29, 397-405.
52. Yanagida T, Tsushima J, Kitamura Y, Yanagisawa D, Takata K, Shibaike T, Yamamoto A, Taniguchi T, Yasui H, Taira T, et al,. (2009) Oxidative stress induction of DJ-1 protein in reactive astrocytes scavenges free radicals and reduces cell injury. Oxid Med Cell Longev 2, 36-42.
53. Canet-Avilés RM, Wilson MA, Miller DW, Ahmad R, McLendon C, Bandyopadhyay S, Baptista MJ, Ringe D, Petsko GA, &, Cookson MR, (2004) The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci USA 101, 9103-9108.
54. Perier C, &, Vila M, (2012) Mitochondrial biology and Parkinson's disease. Cold Spring Harb Perspect Med 2, 1-19.
55. Koopman WJH, Willems PHGM, &, Smeitink JAM, (2012) Monogenic mitochondrial disorders. N Engl J Med 366, 1132-1141.
56. Exner N, Lutz AK, Haass C, &, Winklhofer KF, (2012) Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J 31, 3038-3062.
57. Matsuda W, Furuta T, Nakamura KC, Hioki H, Fujiyama F, Arai R, &, Kaneko T, (2009) Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum. J Neurosci 29, 444-453.
58. Bolam JP, &, Pissadaki EK, (2012) Living on the edge with too many mouths to feed: why dopamine neurons die. Mov Disord 27, 1478-1483.
59. Liang C-L, Wang TT, Luby-Phelps K, &, German DC, (2007) Mitochondria mass is low in mouse substantia nigra dopamine neurons: implications for Parkinson's disease. Exp Neurol 203, 370-380.
60. Sulzer D, &, Surmeier DJ, (2013) Neuronal vulnerability, pathogenesis, and Parkinson's disease. Mov Disord 28, 41-50.
61. Surmeier DJ, &, Sulzer D, (2013) The pathology roadmap in Parkinson disease. Prion 7, 85-91.
62. Yao Z, Gandhi S, Burchell VS, Plun-Favreau H, Wood NW, &, Abramov AY, (2011) Cell metabolism affects selective vulnerability in PINK1-associated Parkinson's disease. J Cell Sci 124, 4194-4202.
63. Chan CS, Gertler TS, &, Surmeier DJ, (2010) A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson's disease. Mov Disord 25 (Suppl 1), S63-S70.
64. Orhan H, Van Holland B, Krab B, Moeken J, Vermeulen NPE, Hollander P, &, Meerman JHN, (2004) Evaluation of a multi-parameter biomarker set for oxidative damage in man: increased urinary excretion of lipid, protein and DNA oxidation products after one hour of exercise. Free Radic Res 38, 1269-1279.
65. Turrens JF, (2003) Mitochondrial formation of reactive oxygen species. J Physiol 552, 335-344.
66. Parker WD, Boyson SJ, &, Parks JK, (1989) Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 26, 719-723.
67. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, &, Marsden CD, (1990) Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54, 823-827.
68. Jenner P, (2003) Oxidative stress in Parkinson's disease. Ann Neurol 53 (Suppl 3), S26-S36.
69. Hattingen E, Magerkurth J, Pilatus U, Mozer A, Seifried C, Steinmetz H, Zanella F, &, Hilker R, (2009) Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease. Brain 132, 3285-3297.
70. Lo S-C, Li X, Henzl MT, Beamer LJ, &, Hannink M, (2006) Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling. EMBO J 25, 3605-3617.
71. Satoh T, Harada N, Hosoya T, Tohyama K, Yamamoto M, &, Itoh K, (2009) Keap1/Nrf2 system regulates neuronal survival as revealed through study of keap1 gene-knockout mice. Biochem Biophys Res Commun 380, 298-302.
72. Tufekci KU, Civi Bayin E, Genc S, &, Genc K, (2011) The Nrf2/ARE pathway: a promising target to counteract mitochondrial dysfunction in Parkinson's disease. Parkinson's Dis 2011, 1-14.
73. Zhang DD, (2010) The Nrf2-Keap1-ARE signaling pathway: the regulation and dual function of Nrf2 in cancer. Antioxid Redox Signal 13, 1623-1626.
74. Lin MT, Cantuti-Castelvetri I, Zheng K, Jackson KE, Tan YB, Arzberger T, Lees AJ, Betensky R, Beal MF, &, Simon DK, (2012) Somatic mitochondrial DNA mutations in early Parkinson and incidental Lewy body disease. Ann Neurol 71, 850-854.
75. Bender A, Krishnan KJ, Morris CM, Taylor G, Reeve AK, Perry RH, Jaros E, Hersheson JS, Betts J, Klopstock T, et al,. (2006) High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 38, 515-517.
76. Funke C, Schneider S, Berg D, &, Kell DB, (2013) Genetics and iron in the systems biology of Parkinson's disease and some related disorders. Neurochem Int 62, 637-652.
77. Wardman P, &, Candeias LP, (1996) Fenton chemistry: an introduction. Radiat Res 145, 523-531.
78. Kehrer JP, (2000) The Haber-Weiss reaction and mechanisms of toxicity. Toxicology 149, 43-50.
79. Hallgren B, &, Sourander P, (1958) The effect of age on the non-haemin iron in the human brain. J Neurochem 3, 41-51.
80. Riederer P, Dirr A, Goetz M, Sofic E, Jellinger K, &, Youdim MB, (1992) Distribution of iron in different brain regions and subcellular compartments in Parkinson's disease. Ann Neurol 32 (Suppl), S101-S104.
81. Ben-Shachar D, Riederer P, &, Youdim MB, (1991) Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J Neurochem 57, 1609-1614.
82. Schweitzer KJ, Brüssel T, Leitner P, Krüger R, Bauer P, Woitalla D, Tomiuk J, Gasser T, &, Berg D, (2007) Transcranial ultrasound in different monogenetic subtypes of Parkinson's disease. J Neurol 254, 613-616.
83. Lv Z, Jiang H, Xu H, Song N, &, Xie J, (2011) Increased iron levels correlate with the selective nigral dopaminergic neuron degeneration in Parkinson's disease. J Neural Transm 118, 361-369.
84. Dusek P, Jankovic J, &, Le W, (2012) Iron dysregulation in movement disorders. Neurobiol Dis 46, 1-18.
85. Schneider S, Paisan-Ruiz C, Quinn NP, Lees AJ, Houlden H, Hardy J, &, Bhatia KP, (2010) ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation. Mov Disord 25, 979-984.
86. McNeill A, (2012) PLA2G6 mutations and other rare causes of neurodegeneration with brain iron accumulation. Curr Drug Targets 13, 1204-1206.
87. Kell DB, (2010) Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. Arch Toxicol 84, 825-889.
88. Jomova K, Vondrakova D, Lawson M, &, Valko M, (2010) Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem 345, 91-104.
89. Ward RJ, Dexter DT, &, Crichton RR, (2012) Chelating agents for neurodegenerative diseases. Curr Med Chem 19, 2760-2772.
90. Sulzer D, (2007) Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci 30, 244-250.
91. Tai H-C, &, Schuman EM, (2008) Ubiquitin, the proteasome and protein degradation in neuronal function and dysfunction. Nat Rev Neurosci 9, 826-838.
92. Fortin DL, Nemani VM, Voglmaier SM, Anthony MD, Ryan TA, &, Edwards RH, (2005) Neural activity controls the synaptic accumulation of alpha-synuclein. J Neurosci 25, 10913-10921.
93. Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK, Chaudhry FA, Nicoll RA, &, Edwards RH, (2010) Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65, 66-79.
94. Bellucci A, Zaltieri M, Navarria L, Grigoletto J, Missale C, &, Spano P, (2012) From α-synuclein to synaptic dysfunctions: new insights into the pathophysiology of Parkinson's disease. Brain Res 1476, 183-202.
95. Lucin KM, &, Wyss-Coray T, (2009) Immune activation in brain aging and neurodegeneration: too much or too little? Neuron 64, 110-122.
96. Nimmerjahn A, Kirchhoff F, &, Helmchen F, (2005) Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308, 1314-1318.
97. Tian L, Rauvala H, &, Gahmberg CG, (2009) Neuronal regulation of immune responses in the central nervous system. Trends Immunol 30, 91-99.
98. Antony PM, Diederich NJ, &, Balling R, (2011) Parkinson's disease mouse models in translational research. Mamm Genome 22, 401-419.
99. Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, Wilson B, Zhang W, Zhou Y, Hong J-S, et al,. (2005) Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 19, 533-542.
100. Alvarez-Erviti L, Couch Y, Richardson J, Cooper JM, &, Wood MJA, (2011) Alpha-synuclein release by neurons activates the inflammatory response in a microglial cell line. Neurosci Res 69, 337-342.
101. Glass CK, Saijo K, Winner B, Marchetto MC, &, Gage FH, (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140, 918-934.
102. Rocha SM, Cristovão AC, Campos FL, Fonseca CP, &, Baltazar G, (2012) Astrocyte-derived GDNF is a potent inhibitor of microglial activation. Neurobiol Dis 47, 407-415.
103. Waak J, Weber SS, Waldenmaier A, Görner K, Alunni-Fabbroni M, Schell H, Vogt-Weisenhorn D, Pham T-T, Reumers V, Baekelandt V, et al,. (2009) Regulation of astrocyte inflammatory responses by the Parkinson's disease-associated gene DJ-1. FASEB J 23, 2478-2489.
104. Mena M, &, García de Yébenes J, (2008) Glial cells as players in parkinsonism: the 'good', the 'bad', and the 'mysterious' glia. Neuroscientist 14, 544-560.
105. Zecca L, Wilms H, Geick S, Claasen J-H, Brandenburg L-O, Holzknecht C, Panizza ML, Zucca F, Deuschl G, Sievers J, et al,. (2008) Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease. Acta Neuropathol 116, 47-55.
106. Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J, Yearout D, Kay DM, Doheny KF, Paschall J, Pugh E, et al,. (2010) Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet 42, 781-785.
107. Brochard V, Combadière B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, Bonduelle O, Alvarez-Fischer D, Callebert J, Launay J, et al,. (2009) Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 119, 182-192.
108. Reynolds AD, Stone DK, Hutter JAL, Benner EJ, Mosley RL, &, Gendelman HE, (2010) Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease. J Immunol 184, 2261-2271.
109. Hirsch EC, Vyas S, &, Hunot S, (2012) Neuroinflammation in Parkinson's disease. Parkinsonism Relat Disord 18 (Suppl 1), S210-S212.
110. Antony PMA, Balling R, &, Vlassis N, (2012) From systems biology to systems biomedicine. Curr Opin Biotechnol 23, 604-608.
111. Ma'ayan A, (2011) Introduction to network analysis in systems biology. Sci Signal 4, tr5
112. Cloutier M, &, Wellstead P, (2010) The control systems structures of energy metabolism. J R Soc 7, 651-665.
113. Wellstead P, &, Cloutier M, (2011) An energy systems approach to Parkinson's disease. Wiley Interdiscip Rev Syst Biol Med 3, 1-6.
114. Magistretti PJ, (2011) Neuron-glia metabolic coupling and plasticity. Exp Physiol 96, 407-410.
115. Wade JJ, McDaid LJ, Harkin J, Crunelli V, &, Kelso JAS, (2011) Bidirectional coupling between astrocytes and neurons mediates learning and dynamic coordination in the brain: a multiple modeling approach. PLoS ONE 6, 1-24.
116. Aubert A, Costalat R, Magistretti PJ, &, Pellerin L, (2005) Brain lactate kinetics: modeling evidence for neuronal lactate uptake upon activation. Proc Natl Acad Sci USA 102, 16448-16453.
117. Perea G, Navarrete M, &, Araque A, (2009) Tripartite synapses: astrocytes process and control synaptic information. Trends Neurosci 32, 421-431.
118. Antony PMA, Trefois C, Stojanovic A, Baumuratov AS, &, Kozak K, (2013) Light microscopy applications in systems biology: opportunities and challenges. Cell Commun Signal 11, 1-19.
119. Jacobs H, Latza U, Vieregge A, &, Vieregge P, (2001) Attitudes of young patients with Parkinson's disease towards possible presymptomatic and prenatal genetic testing. Genet Couns 12, 55-67.
120. Song M, Paul S, Lim H, Dayem AA, &, Cho S-G, (2012) Induced pluripotent stem cell research: a revolutionary approach to face the challenges in drug screening. Arch Pharm Res 35, 245-260.